"In addition to its potential in cancer, recombinant IL-10 has demonstrated anti-inflammatory and anti-fibrotic activities as well as cholesterol lowering abilities in preclinical disease models and in human subjects," commented Carl L. Gordon, Ph.D., C.F.A., partner and co-head of global private equity at OrbiMed, and a member of the ARMO board of directors. "We believe that ARMO is ideally positioned to explore the unique mechanisms of action for this important immunotherapy compound, with possible breakthrough potential in several indications."
ARMO has over 45 issued and pending US and foreign patents and applications covering compositions of matter, methods of use, and methods of manufacturing of AM0010.
About ARMO BioSciences, Inc.
ARMO BioSciences is focused on developing immunotherapies for the treatment of cancer, fibrosis, hypercholesterolemia/atherosclerosis and inflammatory diseases. ARMO believes that by harnessing the body's own capability to arm itself against dysregulated cells, it may provide safer and more effective drugs for patients suffering from grievous diseases. ARMO's medicines are designed to normalize the underlying biology of disease through immunotherapeutic mechanisms for sustained and durable responses. Founded in 2012, ARMO is backed by investors Kleiner Perkins Caufield & Byers, OrbiMed and DAG Ventures.
About Kleiner Perkins Caufield & Byers
Kleiner Perkins Caufield & Byers (KPCB) has backed entrepreneurs in more than 500 ventures leading to 150 IPOs, 350,000 jobs and a deep strategic network. The firm has helped build pioneering companies like Amazon, Electronic Arts, Genentech,
|SOURCE ARMO BioSciences, Inc.|
Copyright©2012 PR Newswire.
All rights reserved